紧密连接蛋白claudin 18.2(CLDN18.2)在胃癌和胰腺癌等恶性肿瘤中异常高表达,基于其高组织特异性、广泛患者覆盖性及多技术路径开发潜力,成为癌症治疗领域备受关注的新靶点。近年来,针对CLDN18.2的创新药物研发取得显著突破,尤其是首个...紧密连接蛋白claudin 18.2(CLDN18.2)在胃癌和胰腺癌等恶性肿瘤中异常高表达,基于其高组织特异性、广泛患者覆盖性及多技术路径开发潜力,成为癌症治疗领域备受关注的新靶点。近年来,针对CLDN18.2的创新药物研发取得显著突破,尤其是首个靶向CLDN18.2的抗体药物zolbetuximab于2024年在日本获批上市,标志着CLDN18.2靶向治疗进入新阶段。综述CLDN18.2作为肿瘤治疗靶点的生物学基础,重点介绍针对该靶点的抗体药物、抗体药物偶联物(antibody drug conjugate,ADC)、嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法及放射性核素偶联药物(radionuclide drug conjugate,RDC)等治疗策略的研究进展,旨在为CLDN18.2靶向药物进一步研发与临床应用提供参考。展开更多
The treatment of gastrointestinal cancer has always been a crucial research area,and targeted therapy has been receiving increasing attention.At present,the effect of targeted therapy is unsatisfactory for gastric can...The treatment of gastrointestinal cancer has always been a crucial research area,and targeted therapy has been receiving increasing attention.At present,the effect of targeted therapy is unsatisfactory for gastric cancer.Thus,the discovery of new targets is crucial.Claudin 18.2(CLDN18.2),a member of the claudin family,belongs to the tight junction protein family that controls the flow of molecules between cell layers.CLDN18.2 expression has been discussed in many studies.In recent years,there have been many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362.Furthermore,CLDN18.2-specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors,such as gastric and pancreatic cancers.Considerable research has been focused on CLDN18.2.CLDN18.2,a newly discovered marker for precise targeted therapy of gastric cancer,could offer new hope for the treatment of gastric cancer.展开更多
文摘紧密连接蛋白claudin 18.2(CLDN18.2)在胃癌和胰腺癌等恶性肿瘤中异常高表达,基于其高组织特异性、广泛患者覆盖性及多技术路径开发潜力,成为癌症治疗领域备受关注的新靶点。近年来,针对CLDN18.2的创新药物研发取得显著突破,尤其是首个靶向CLDN18.2的抗体药物zolbetuximab于2024年在日本获批上市,标志着CLDN18.2靶向治疗进入新阶段。综述CLDN18.2作为肿瘤治疗靶点的生物学基础,重点介绍针对该靶点的抗体药物、抗体药物偶联物(antibody drug conjugate,ADC)、嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法及放射性核素偶联药物(radionuclide drug conjugate,RDC)等治疗策略的研究进展,旨在为CLDN18.2靶向药物进一步研发与临床应用提供参考。
文摘The treatment of gastrointestinal cancer has always been a crucial research area,and targeted therapy has been receiving increasing attention.At present,the effect of targeted therapy is unsatisfactory for gastric cancer.Thus,the discovery of new targets is crucial.Claudin 18.2(CLDN18.2),a member of the claudin family,belongs to the tight junction protein family that controls the flow of molecules between cell layers.CLDN18.2 expression has been discussed in many studies.In recent years,there have been many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362.Furthermore,CLDN18.2-specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors,such as gastric and pancreatic cancers.Considerable research has been focused on CLDN18.2.CLDN18.2,a newly discovered marker for precise targeted therapy of gastric cancer,could offer new hope for the treatment of gastric cancer.
